Content Type: Commentary & Opinion

March-In Guidance for Publicly Funded Drugs: A Necessary Safety Net for Patients

March 6, 2026

Overcoming Challenges to Implementing New Evidence for Low-Dose Anticoagulant Use in Peripheral Artery Disease

March 6, 2026

Why Some Patients Overpay for Specialty Generic Drugs

March 6, 2026

Preserving Timely Generic Drug Competition with Legislation on “Skinny Labeling”

March 6, 2026

Complicated Regulatory Decision-Making Following Inconsistent Trial Results: The Issue with Ibrutinib for Mantle Cell Lymphoma

March 6, 2026

Improving Drug Supply Chain Security

March 6, 2026

The Problem of Limited-Supply Agreements for Medicare Price Negotiation

March 6, 2026

Free Speech Challenges to the Inflation Reduction Act

March 6, 2026

Wedding Websites, Free Speech, and Adverse Drug Effects

March 6, 2026

Op-Ed: We Can’t Let Drug Companies Get Out of Negotiating Prices

March 6, 2026

Fairer Returns on Public Investments

March 6, 2026

Will Medicare Price Negotiation Delay Cancer-Drug Launches?

March 6, 2026